Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 330 participants.

Also called NCT01252420

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01252420
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, New Zealand (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01252420. Allocation not applicable; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2013-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis
Acronym
TWISTER
Condition
Venous Thrombosis
Intervention (Drug)
Enoxaparin
Lead sponsor
Monash Medical Centre (class: other)
Collaborator
Southern Health, Victoria (class: not stated)
Collaborator
Eastern Health, Victoria (class: not stated)
Collaborator
Royal Adelaide Hospital (class: other)
Collaborator
Prince of Wales Hospital, Sydney (class: other government)
Collaborator
Christchurch Hospital (class: other)
Collaborator
Auckland City Hospital (class: other government)
Collaborator
North Shore Hospital, New Zealand (class: other)
Collaborator
Middlemore Hospital, New Zealand (class: other)

Record details

Record id
cardio:ct-nct01252420
Content hash
8c05b7f94e3977e1bf9b81ed0b9ac957d1a27ba147e6ec3044e7aa2760bb65d2